"MEND respiratory distress clinical trial underwayPatient...

"MEND respiratory distress clinical trial underway
Patient recruitment and treatment in the MEND trial is presently expected to complete later this year. Recognising
the slower than anticipated recruitment, arising primarily from challenges in the hospital system, St George
Hospital in the South Eastern Sydney Local Health District has been added as a new site for the MEND clinical trial.
The hospital is the largest within the district with 550 beds and is amongst the leading centres for trauma and
emergency management in the state. St George Hospital is seeking to recruit additional patients in the trial,
thereby accelerating the recruitment process, which forms part of Cynata’s mitigation strategies to ensure that
the trial is completed by the end of the year. If successful, the findings from this trial could form the foundation
for further indications such as Acute Respiratory Distress Syndrome (ARDS), sepsis and cytokine release syndrome
(CRS), which are associated with the excessive inflammatory responses typically seen in patients experiencing
respiratory distress. Pre-clinical studies have shown that these conditions can potentially be improved with
Cymerus MSCs through modulation of the inflammatory reaction associated with these diseases, with a combined
market opportunity (ARDS, sepsis and CRS) of over US$8bn.2"

27 July 2022
https://app.sharelinktechnologies.com/announcement/asx/57da4e62e7cc0c7eefc30395df7a9f59

Dr Ross Macdonald, Cynata’s Chief Executive Officer, said:
“We operate in a highly dynamic environment and the situation around the MEND clinical trial has
certainly exhibited a fast-moving landscape. The widespread uptake of COVID-19 and influenza vaccines,
availability of new antiviral drugs, along with vastly improved patient management practices in our
target population, have had very significant effects on the trial and the availability of eligible patients.
These effects have had to be factored into our plans to ensure an optimal risk profile and allocation of
resources across our clinical pipeline. Our strategic portfolio review was intended to ensure that we focus
the application of resources on only the most viable opportunities and continuing to pursue the MEND
trial no longer had alignment with that goal.The decision allows us to refocus our resources on, and
maintain our commitment to, our other promising clinical programs.”

12 August 2022. https://app.sharelinktechnologies.com/announcement/asx/1ea5b5a557c9ba4d1b2e4dfb7994ac00